144 related articles for article (PubMed ID: 8869127)
1. Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: a theory.
Zhu BT
J Theor Biol; 1996 Aug; 181(3):273-91. PubMed ID: 8869127
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic explanation for the unique pharmacologic properties of receptor partial agonists.
Zhu BT
Biomed Pharmacother; 2005 Apr; 59(3):76-89. PubMed ID: 15795100
[TBL] [Abstract][Full Text] [Related]
3. Partial agonism: mechanisms based on ligand-receptor interactions and on stimulus-response coupling.
Pliska V
J Recept Signal Transduct Res; 1999; 19(1-4):597-629. PubMed ID: 10071788
[TBL] [Abstract][Full Text] [Related]
4. Modification of dose-response curves by effector blockade and uncompetitive antagonism.
Pennefather P; Quastel DM
Mol Pharmacol; 1982 Sep; 22(2):369-80. PubMed ID: 6292695
[TBL] [Abstract][Full Text] [Related]
5. Identification of competitive antagonists of the P2Y1 receptor.
Boyer JL; Romero-Avila T; Schachter JB; Harden TK
Mol Pharmacol; 1996 Nov; 50(5):1323-9. PubMed ID: 8913364
[TBL] [Abstract][Full Text] [Related]
6. Investigation into the contractile response of melatonin in the guinea-pig isolated proximal colon: the role of 5-HT4 and melatonin receptors.
Lucchelli A; Santagostino-Barbone MG; Tonini M
Br J Pharmacol; 1997 Aug; 121(8):1775-81. PubMed ID: 9283717
[TBL] [Abstract][Full Text] [Related]
7. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
de Boer SF; Koolhaas JM
Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells.
Nonno R; Lucini V; Pannacci M; Mazzucchelli C; Angeloni D; Fraschini F; Stankov BM
Br J Pharmacol; 1998 Jun; 124(3):485-92. PubMed ID: 9647472
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
10. Identification of new gonadotrophin-releasing hormone partial agonists.
Leaños-Miranda A; Ulloa-Aguirre A; Cervini LA; Janovick JA; Rivier J; Conn PM
J Endocrinol; 2006 Jun; 189(3):509-17. PubMed ID: 16731782
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
12. Agonist actions of neonicotinoids on nicotinic acetylcholine receptors expressed by cockroach neurons.
Tan J; Galligan JJ; Hollingworth RM
Neurotoxicology; 2007 Jul; 28(4):829-42. PubMed ID: 17561262
[TBL] [Abstract][Full Text] [Related]
13. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Zhu J; Luo LY; Li JG; Chen C; Liu-Chen LY
J Pharmacol Exp Ther; 1997 Aug; 282(2):676-84. PubMed ID: 9262330
[TBL] [Abstract][Full Text] [Related]
14. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
[TBL] [Abstract][Full Text] [Related]
15. Specific GABA(A) agonists and partial agonists.
Krogsgaard-Larsen P; Frølund B; Liljefors T
Chem Rec; 2002; 2(6):419-30. PubMed ID: 12469353
[TBL] [Abstract][Full Text] [Related]
16. Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles.
Davies DJ; Garratt PJ; Tocher DA; Vonhoff S; Davies J; Teh MT; Sugden D
J Med Chem; 1998 Feb; 41(4):451-67. PubMed ID: 9484496
[TBL] [Abstract][Full Text] [Related]
17. GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic.
Krogsgaard-Larsen P; Frølund B; Liljefors T; Ebert B
Biochem Pharmacol; 2004 Oct; 68(8):1573-80. PubMed ID: 15451401
[TBL] [Abstract][Full Text] [Related]
18. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations.
Seifert R; Wenzel-Seifert K; Gether U; Kobilka BK
J Pharmacol Exp Ther; 2001 Jun; 297(3):1218-26. PubMed ID: 11356949
[TBL] [Abstract][Full Text] [Related]
19. Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists.
Chen Y; Chen C; Wang Y; Liu-Chen LY
J Pharmacol Exp Ther; 2006 Nov; 319(2):765-75. PubMed ID: 16882876
[TBL] [Abstract][Full Text] [Related]
20. Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses.
Baker JG; Hall IP; Hill SJ
Mol Pharmacol; 2003 Sep; 64(3):679-88. PubMed ID: 12920204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
